Autres langues Summit Therapeutics Inc.

Actions

SMMT

US86627T1088

Temps réel estimé Cboe BZX Autres places de cotation 21:02:50 02/05/2024			Varia. 5j.	Varia. 1 janv.
4,035 ^USD	-14,15 %		+15,07 %	+56,51 %

01/05	Transcript : Summit Therapeutics Inc., Q1 2024 Earnings Call, May 01, 2024
01/05	Summit Therapeutics Inc. annonce ses résultats pour le premier trimestre clos le 31 mars 2024	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2024	01/05
Summit Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	01/05
Summit Therapeutics to Host First Quarter 2024 Financial Results & Operational Progress Call on May 1, 2024	24/04
Summit Therapeutics Appoints Dr. Mostafa Ronaghi, Renowned Executive and Genomicist, to its Board of Directors	11/04
Summit Therapeutics Inc. Appoints Dr. Mostafa Ronaghi to Its Board of Directors	11/04
Summit Therapeutics to Present at the Stifel 2024 Targeted Oncology Forum	10/04
Illumina CFO Goswami to depart, former Summit Therapeutics exec Dhingra to succeed	09/04
Illumina Names Ankur Dhingra as Chief Financial Officer	09/04
Illumina CFO Goswami to depart, Summit Therapeutics' Dhingra named successor	09/04
Summit Therapeutics Appoints COO to Additional Role of CFO	04/04
Summit Therapeutics Inc. Announces Chief Financial Officer Changes	03/04
Summit Therapeutics Inc. Appoints Bhaskar Anand as Chief Accounting Officer, Head of Finance, to Serve as Its Principal Accounting Officer	03/04
Pulse Biosciences Shares Fall After Q4 Results, Rights Issue Plans	01/04
Summit Therapeutics Insider Bought Shares Worth $375,000, According to a Recent SEC Filing	28/03
Summit Therapeutics Inc. - Promising Intracranial Anti-Tumor Activity and Safety Data for Ivonescimab in NSCLC Patients with Brain Metastases Featured at ELCC 2024	25/03
Summit Therapeutics Reports 23% Complete Response in Metastatic NSCL Cancer Drug Ivonescimab's Clinical Trials	22/03
Promising Intracranial Anti-Tumor Activity and Safety Data for Ivonescimab in NSCLC Patients with Brain Metastases Featured at ELCC 2024	22/03
Summit Therapeutics Inc. Announces Promising Intracranial Anti-Tumor Activity and Safety Data for Ivonescimab in NSCLC Patients with Brain Metastases Featured at ELCC 2024	22/03
Akeso Logs First-Ever Profit in 2023; Beats EPS Forecast	19/03
Summit Therapeutics Inc.(NasdaqGM:SMMT) added to S&P Biotechnology Select Industry Index	18/03

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Summit Therapeutics Inc.

Actions

SMMT

US86627T1088

Autres langues

Filtres